4.7 Review

Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events

期刊

ARCHIVES OF TOXICOLOGY
卷 96, 期 1, 页码 11-78

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00204-021-03171-4

关键词

Chemobrain; Chemofog; Neurotoxicity; Cognitive impairment; Chemotherapy

资金

  1. FCT-Fundacao para a Ciencia e a Tecnologia, I.P. [UIDP/04378/2020, UIDB/04378/2020, LA/P/0140/2020]
  2. Associate Laboratory Institute for Health and Bioeconomy-i4HB [EXPL/MED-FAR/0203/2021]
  3. Innovative Medicines Initiative 2 Joint Undertaking [821528]
  4. European Union
  5. European Federation of Pharmaceutical Industries and Associations (EFPIA)
  6. FCT [SFRH/BD/129359/2017]
  7. UCIBIO [UI/BD/151318/2021]
  8. FCT under the Norma Transitoria [DL57/2016/CP1334/CT0006]
  9. Fundação para a Ciência e a Tecnologia [EXPL/MED-FAR/0203/2021, SFRH/BD/129359/2017] Funding Source: FCT

向作者/读者索取更多资源

Chemotherapy-induced cognitive dysfunction has a significant impact on cancer patients, affecting domains such as verbal memory and psychomotor function. Studies suggest that chemotherapy alters brain metabolism, white and grey matter, while the underlying neurotoxic mechanism of cognitive deficits is still not fully elucidated.
Cognitive dysfunction has been one of the most reported and studied adverse effects of cancer treatment, but, for many years, it was overlooked by the medical community. Nevertheless, the medical and scientific communities have now recognized that the cognitive deficits caused by chemotherapy have a strong impact on the morbidity of cancer treated patients. In fact, chemotherapy-induced cognitive dysfunction or 'chemobrain' (also named also chemofog) is at present a well-recognized effect of chemotherapy that could affect up to 78% of treated patients. Nonetheless, its underlying neurotoxic mechanism is still not fully elucidated. Therefore, this work aimed to provide a comprehensive review using PubMed as a database to assess the studies published on the field and, therefore, highlight the clinical manifestations of chemobrain and the putative neurotoxicity mechanisms. In the last two decades, a great number of papers was published on the topic, mainly with clinical observations. Chemotherapy-treated patients showed that the cognitive domains most often impaired were verbal memory, psychomotor function, visual memory, visuospatial and verbal learning, memory function and attention. Chemotherapy alters the brain's metabolism, white and grey matter and functional connectivity of brain areas. Several mechanisms have been proposed to cause chemobrain but increase of proinflammatory cytokines with oxidative stress seem more relevant, not excluding the action on neurotransmission and cellular death or impaired hippocampal neurogenesis. The interplay between these mechanisms and susceptible factors makes the clinical management of chemobrain even more difficult. New studies, mainly referring to the underlying mechanisms of chemobrain and protective measures, are important in the future, as it is expected that chemobrain will have more clinical impact in the coming years, since the number of cancer survivors is steadily increasing.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据